Biotech News
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026.
Plenary/Panel Discussion Details:
Panel Discussion: ADC Licensing, Partnering & Investment Session Sutro Participant: Hans-Peter Gerber, Ph.D.
Date/Time: February 23, 2026, 3:00PM GMT
Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies Sutro Participant: Hans-Peter Gerber, Ph.D.
Date/Time: February 24, 2026, 7:45AM GMT
Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms Presenter: Hans-Peter Gerber, Ph.D.
Date/Time: February 25, 2026, 9:00AM GMT
Following the event, the content from the plenary session will be made available in the Scientific Publications section of Sutro Biopharma’s website at www.sutrobio.com .
About Sutro Biopharma Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com .
Investor Contact Emily White Sutro Biopharma (650) 823-7681 [email protected]
Media Contact Amy Bonanno Lyra Strategic Advisory [email protected]